PrognosisA $2.8 Million Miracle Therapy Eludes Some Long-Suffering PatientsBluebird Bio’s Zynteglo could cure beta thalassemia, yet some older people with the disease say they have faced difficulties in trying to get treated
BusinessIllumina’s Sudden CEO Exit Is Just One of Many Problems Facing DNA CompanyThe sudden resignation of Francis deSouza raises questions about the firm’s future after its proxy fight with Carl Icahn.
BusinessBiogen’s CEO Says He Doesn’t Want ‘Whole Portfolio of Moonshots’Christopher Viehbacher will consider acquisitions to expand the company’s focus beyond difficult brain diseases like Alzheimer’s and Parkinson’s.
